The research team focused on a transcription factor called CCAAT/enhancer binding protein beta, or C/EBPβ, a DNA-binding protein known to regulate inflammatory and stress-response genes throughout the body. In the brain, C/EBPβ has previously attracted attention in neurodegeneration research, where elevated levels have been linked to the activation of asparagine endopeptidase, or AEP, a protease also known as legumain. AEP is an enzyme with a taste for particular asparagine residues, and when it becomes active it can cleave key neuronal proteins, destabilizing the delicate architecture of synapses. The Wuhan group hypothesized that this same transcription factor-to-protease circuit might be recruited by chronic stress in ways that erode synaptic homeostasis and precipitate the behavioral core of depression.

To test the idea, the researchers used a well-established rodent paradigm called chronic unpredictable mild stress, or CUMS, in which animals are exposed over weeks to a rotating series of low-grade stressors — altered light cycles, damp bedding, tilted cages, and other unpredictable annoyances. The approach reliably produces animals that show anhedonia, behavioral despair, and other measurable depression-like phenotypes, making it a standard preclinical proxy for the human disorder. When the team examined the hippocampus, a brain region indispensable for mood regulation and memory that is consistently implicated in stress-related psychiatric illness, they found that chronic stress activated C/EBPβ and drove up the expression of its downstream protease target, AEP. The pathway, in other words, is not a bystander in the stressed brain; it is switched on precisely where and when synaptic function begins to falter.

The causal experiments that followed form the evidentiary heart of the paper. When the researchers genetically knocked out C/EBPβ, the animals were substantially protected: the depression-like phenotypes induced by chronic unpredictable mild stress were alleviated, indicating that the transcription factor is required for stress to exert its full behavioral toll. A parallel experiment deleting AEP produced a similar protective effect, placing the protease downstream in the same causal chain. These loss-of-function results were complemented by gain-of-function studies that flipped the logic in the opposite direction. When the team overexpressed either C/EBPβ or AEP directly in the hippocampus of otherwise healthy animals, the depression-like phenotypes appeared without any external stress at all — a striking demonstration that elevating this single pathway is sufficient to reproduce the behavioral signature of chronic stress exposure.

Perhaps the most conclusive experiment was the epistasis test, a genetic technique used to establish the ordering of components within a pathway. If AEP truly acts downstream of C/EBPβ, then removing AEP should blunt the damage caused by forcing C/EBPβ into overdrive. That is exactly what the researchers observed: genetic deletion of AEP attenuated the detrimental effects induced by C/EBPβ overexpression. The result confirms a clean linear relationship — stress activates C/EBPβ, C/EBPβ elevates AEP, and AEP executes the synaptic sabotage that manifests as depression-like behavior. Taken together, the knockout, overexpression, and rescue experiments satisfy the classic criteria for causation in molecular medicine, elevating the C/EBPβ/AEP axis from correlation to mechanism.

Why does this matter for understanding depression itself? For decades, the dominant framework for stress-related mood disorders centered on monoamine neurotransmitters such as serotonin and norepinephrine, a view that produced widely prescribed antidepressants but left many patients without adequate relief. More recent scholarship has emphasized synaptic homeostasis — the brain’s ability to maintain the strength, number, and plasticity of connections between neurons — as a substrate of resilient mood regulation. Chronic stress is known to cause atrophy of dendritic spines and loss of synapses in the hippocampus and prefrontal cortex, and effective antidepressant treatments often restore synaptic connectivity. The new study supplies a concrete molecular route by which that synaptic erosion happens: a stress-activated transcription factor induces a protease that degrades the protein infrastructure of the synapse. In this framing, depression is not merely a chemical imbalance but a structural and enzymatic dismantling of the brain’s communication hardware.

The identification of AEP as the effector arm of the pathway is particularly intriguing from a therapeutic standpoint. Proteases are among the most druggable enzyme classes in biology, and inhibitors targeting legumain have already been explored in oncology and neurodegenerative disease contexts. The finding that AEP deletion protects animals from depression-like phenotypes, while its hippocampal overexpression is sufficient to induce them, suggests that a pharmacological inhibitor of AEP — or an intervention that dampens C/EBPβ activity upstream — could in principle interrupt the cascade before synapses are lost. The authors’ demonstration that removing AEP rescues the damage caused by C/EBPβ overexpression provides a direct proof of concept for that strategy, although the distance between mouse genetics and a human therapy remains considerable.

Important caveats temper the translation. The study relies on animal models whose fidelity to human depression, while well validated, is imperfect; a rodent’s immobility in a forced swim test or its indifference to sucrose is not the same as the richly subjective experience of human despair. The hippocampus is also only one node in the distributed circuitry of mood, and stress is known to act on the prefrontal cortex, amygdala, and neuroendocrine systems in parallel. C/EBPβ is a pleiotropic transcription factor with essential roles in immune function and metabolism, so systemic suppression would carry risks that targeted brain delivery might avoid. Nonetheless, the mechanistic clarity of the pathway — a defined transcriptional trigger, a defined enzymatic effector, and bidirectional genetic evidence — gives the field a sharper set of questions to pursue in human tissue, human genetics, and clinical cohorts.

The work also connects depression to a broader theme in modern neuroscience: the shared vulnerability pathways that cut across seemingly distinct brain diseases. AEP has been implicated in Alzheimer’s disease, where it cleaves tau and other proteins, and C/EBPβ activation has been documented in aging and neuroinflammatory states. The new findings raise the possibility that chronic stress co-opts an ancient damage-response program — one that normally helps cells cope with injury — and that its sustained activation in mood circuitry becomes pathological. This overlap may help explain epidemiological observations that chronic stress, depression, and neurodegenerative risk travel together, and it positions the C/EBPβ/AEP axis as a candidate convergence point where psychiatric and neurodegenerative research can inform each other.

For now, the immediate significance of the study lies in its demonstration that a single, manipulable molecular pathway can carry much of the weight of stress-induced synaptic impairment and depression-like behavior. By showing that the pathway is both necessary — its removal protects — and sufficient — its activation harms — the Wuhan team has converted a diffuse clinical problem into a defined set of molecular targets. As the authors and their colleagues at Wuhan University, supported by the National Natural Science Foundation of China and provincial funding programs, continue to dissect how AEP remodels synaptic proteins under stress, the prospect of interventions that preserve synaptic integrity in the face of chronic stress moves from speculation toward testable strategy. For the millions of people whose depression resists current treatments, that shift in the mechanistic landscape is reason for measured but genuine optimism.

Subject of Research: The role of the C/EBPβ/AEP molecular pathway in chronic stress-induced synaptic impairment and depression

Article Title: C/EBPβ/AEP pathway mediates synaptic impairments and depression-like phenotypes induced by chronic stress

Article References: Xiong, M., Xia, D., Yang, Y., Li, Y., Pan, L., Liu, C., Chen, Q., Zhang, Z., Xu, X., & Meng, L. (2026). C/EBPβ/AEP pathway mediates synaptic impairments and depression-like phenotypes induced by chronic stress. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06426-4

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06426-4

Keywords: depression, chronic stress, C/EBPβ, AEP, legumain, synapses, hippocampus, neuroinflammation, transcription factor, protease, mental health, preclinical models

The review, conducted by a team led by Giacomo Colella, Valentina Piccioni, and Gianmarco Contino of the University of Birmingham, adhered to the PRISMA 2020 reporting guidelines and searched the PubMed database for studies published between 2000 and 2025. The team focused specifically on in vitro and ex vivo models of solid tumors that had been tested in an immuno-oncology context, deliberately excluding animal studies to concentrate on human-relevant laboratory platforms. From this search, the researchers identified 75 studies that met their inclusion criteria, spanning six principal experimental model types and 23 different cancer types, with lung, breast, and colorectal cancers appearing most frequently in the literature.

The six model categories catalogued in the review represent a spectrum of biological fidelity and technical simplicity. Two-dimensional cell line cultures, the workhorse of cancer biology for decades, remain valuable for rapid initial screening of immunotherapeutic compounds. Three-dimensional spheroid cultures introduce a level of spatial organization that better recapitulates the architecture of tumors, including nutrient and oxygen gradients that influence immune cell behavior. Patient-derived organoids, or PDOs, go further by preserving many of the genetic and phenotypic characteristics of the original tumor from which they were grown, offering a personalized window into how an individual patient’s cancer might respond to immunotherapy.

At the ex vivo end of the spectrum, tumor tissue slices preserve the native architecture of the tumor microenvironment, including its stromal cells, extracellular matrix, and endogenous immune infiltrate, although they can typically be maintained in culture only for short windows of time. Tumor-on-a-chip systems, often built from polydimethylsiloxane or cyclic olefin copolymer, add another dimension of realism by enabling controlled perfusion, the establishment of chemical gradients, and the observation of immune cell trafficking under dynamic flow conditions that mimic the vasculature. The review also noted a residual category of other model types, including immune co-culture cell microarrays and platforms derived from circulating tumor cells or induced pluripotent stem cells.

On the immunotherapy side, the studies surveyed by the review interrogated a range of treatment modalities. Immune checkpoint inhibitors, particularly antibodies targeting the programmed death-1 receptor and its ligand PD-L1, dominated the landscape, reflecting their clinical prominence. Adoptive cell therapies formed the second major pillar, encompassing chimeric antigen receptor T cells, tumor-infiltrating lymphocytes, and natural killer cell-based approaches. The immune cell types most commonly incorporated into these experimental systems were T lymphocytes, including both tumor-infiltrating lymphocytes and CAR-T cells, followed by natural killer cells, a distribution that mirrors the current emphasis of clinical immuno-oncology.

A central theme of the review is the concept of transferability, meaning the degree to which findings generated in one model system can be generalized to other models, to different cancer types, and ultimately to patients. The authors recorded the culture setup, validation status, and species of origin for each study to enable contextual comparison across platforms. Their analysis suggests that no single model is sufficient on its own: two-dimensional cultures are useful for hypothesis generation and high-throughput screening, but they strip away the spatial and stromal context that governs immune cell function in real tumors. Three-dimensional spheroids and organoids restore much of that context, and organoids in particular retain patient-specific characteristics that make them attractive for precision immuno-oncology, yet they typically lack a complete immune component unless immune cells are deliberately co-cultured.

Tumor tissue slices occupy a distinctive niche because they retain the endogenous immune microenvironment, including tumor-associated macrophages, cancer-associated fibroblasts, regulatory T cells, and myeloid-derived suppressor cells, all of which are increasingly recognized as critical determinants of immunotherapy response and resistance. The limitation is practical rather than conceptual: slice viability declines over days, restricting the duration of experiments and complicating the assessment of therapies that require prolonged immune priming. Tumor-on-a-chip devices, by contrast, can sustain perfused cultures for longer periods and allow researchers to observe how immune cells migrate, extravasate, and infiltrate tumor tissue under physiologically relevant flow, but they demand specialized engineering expertise and remain difficult to standardize across laboratories.

The systematic nature of the review, prospectively registered with PROSPERO under registration number CRD420251153061, lends weight to its conclusions. The authors extracted data across defined domains including model type, immune cell representation, the class of immunotherapy assessed, and measures of transferability, summarizing the results into structured tables intended to serve as a practical reference. The work was supported by a Cancer Research UK Training Fellowship and by the European COST Action CA21135, and the authors acknowledged the Queen Elizabeth Upper Gastrointestinal Cancer Patient Group for its input. The team declared no competing interests, and because the review relied exclusively on publicly available published data, no primary patient samples or ethical approvals were required.

The practical significance of this catalogue lies in its potential to reduce the attrition that has plagued immuno-oncology drug development. Many immunotherapeutic agents that show promise in simplified laboratory systems fail in clinical trials, a pattern that experts attribute in part to the mismatch between conventional preclinical models and the immunologically complex reality of human tumors. By providing a curated, searchable dataset of 75 studies organized by model type, cancer type, immune context, and therapy class, the review gives researchers a tool for selecting the most appropriate platform for a given experimental question, whether that involves screening checkpoint inhibitor combinations in organoids, testing CAR-T cell cytotoxicity in spheroids, or probing immune trafficking in microfluidic chips.

The review also highlights gaps that the field must address. The representation of immune cell types remains narrow, with myeloid populations and dendritic cells underrepresented relative to T cells and natural killer cells, despite their established roles in shaping antitumor immunity. Validation standards vary widely across studies, and the authors note that culture conditions, extracellular matrix substitutes such as basement membrane extract, and air-liquid or gel-liquid interface techniques differ enough to complicate cross-study comparisons. As cancer immunotherapy continues to expand into new modalities and tumor types, the Birmingham team’s systematic inventory provides both a snapshot of current practice and a benchmark against which the next generation of preclinical platforms can be measured, bringing the laboratory one step closer to faithfully predicting which patients will benefit from the immune-based treatments reshaping modern oncology.

Subject of Research: A systematic review of in vitro and ex vivo preclinical models used to evaluate cancer immunotherapy in solid tumors

Article Title: Preclinical models for cancer immunotherapy: a systematic review of ex vivo and in vitro platforms

Article References: Colella, G., Piccioni, V., Swirsky, F., Kunene, V., & Contino, G. (2026). Preclinical models for cancer immunotherapy: a systematic review of ex vivo and in vitro platforms. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04494-w

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04494-w

Keywords: cancer immunotherapy, patient-derived organoids, immune checkpoint inhibitors, CAR-T cells, tumor tissue slices, tumor-on-a-chip, 3D spheroids, tumor microenvironment, adoptive cell therapy, preclinical models, natural killer cells, systematic review

The research, led by Sylvain Gourier and Marwan Bouras of Brest University Hospital Centre in France, together with colleagues in Quebec and Nantes, set out to answer a deceptively simple question: when AMPA receptor antagonists are administered after a traumatic brain injury in mammals, do they actually make things better? The team searched three major biomedical databases, MEDLINE, Embase and Web of Science, and screened 410 records to arrive at a final set of eleven studies that met their strict inclusion criteria. Only mammalian in vivo experiments in which an AMPA receptor antagonist was given after the injury and compared against a vehicle control, no treatment, or an alternative intervention were eligible, a design intended to mirror as closely as possible the clinical scenario in which a patient arrives at a hospital after the insult has already occurred.

The biological rationale behind this line of investigation runs deep. When the brain is subjected to mechanical trauma, damaged and dying cells flood the extracellular space with glutamate, the principal excitatory neurotransmitter of the central nervous system. Under normal conditions, glutamate transmission is tightly regulated, but after injury the excess glutamate overstimulates its receptors, provoking a cascade known as excitotoxicity. Calcium floods into neurons through ion channels, mitochondrial function collapses, free radicals accumulate, and cells that survived the initial blow die a slow secondary death over hours to days. Because this secondary injury unfolds on a timescale that leaves a therapeutic window, interrupting it with receptor blockers has long been an attractive strategy. Previous attempts targeting the related NMDA receptor ultimately failed in human trials, but the AMPA receptor, which mediates the fast component of excitatory synaptic transmission and can become calcium-permeable after injury, has re-emerged as a distinct and possibly more tractable target.

To conduct the meta-analysis, two reviewers independently screened the candidate studies, extracted the data and appraised methodological quality and risk of bias using two established instruments: the CAMARADES checklist, developed specifically for pooling animal data from experimental studies, and the SYRCLE tool, which probes sources of bias in laboratory animal research. The primary outcome was neurobehavioural performance, assessed across three distinct domains: neurological deficit, cognition and memory, and motor coordination. Secondary outcomes included the severity of brain lesions, mortality, and inflammatory biomarkers. The team applied random-effects meta-analysis, expressing treatment effects as standardized mean differences, a statistical approach that allows results measured on different behavioural scales in different laboratories to be combined into a single estimate.

The headline result is striking for cognition. Across five studies, AMPA receptor antagonists produced a large improvement in cognition and memory, with a standardized mean difference of 1.53 and a tight 95 percent confidence interval running from 1.06 to 2.01. Perhaps more importantly for the credibility of the finding, the statistical heterogeneity across these studies was almost nonexistent, with an I-squared value of just 3 percent, meaning the effect was remarkably consistent from one experiment to the next. In a field where preclinical results often vary wildly between laboratories, this kind of uniformity is rare and lends considerable weight to the conclusion that AMPA blockade genuinely protects the injured, memory-forming circuits of the hippocampus and surrounding structures.

Neurological deficit scores also favoured the drug-treated animals, with a standardized mean difference of 1.28 across four studies, although the confidence interval here, stretching from 0.05 to 2.50, barely excludes zero and the heterogeneity was high at 78 percent, signalling that study designs, drug choices or injury models differed in ways that materially affected the results. Motor coordination told a different story altogether: pooling two studies yielded a standardized mean difference of minus 1.00 with a confidence interval spanning from minus 2.96 to 0.96 and extreme heterogeneity of 83 percent, which the authors interpret as no reliable benefit for motor function. This dissociation between cognitive and motor outcomes is biologically plausible, since AMPA receptor signalling is central to synaptic plasticity in memory circuits, while motor recovery after trauma may depend on mechanisms that pharmacological receptor blockade cannot rescue, or may even require intact AMPA-mediated signalling for compensatory plasticity to occur.

Beyond behaviour, the drugs left visible marks on the injured brain itself. In seven studies measuring lesion severity, AMPA receptor antagonists significantly reduced the extent of tissue damage, with a standardized mean difference of minus 1.39 and moderate heterogeneity of 53 percent. The included experiments spanned several generations of compounds, from early competitive antagonists such as NBQX and the quinoxalinediones ZK200775 and YM872 to the noncompetitive agent talampanel and, more recently, perampanel, the first AMPA antagonist approved for clinical use as an antiepileptic drug. Several of the newer studies also documented consistent reductions in inflammatory biomarkers, aligning with work showing that perampanel dampens oxidative stress, pyroptosis and neuroinflammation through pathways involving molecules such as Sirt3, and protects the neurovascular unit that maintains the blood-brain barrier. Mortality, by contrast, showed no significant effect, a reminder that preventing cellular cascades of damage does not necessarily translate into survival advantages in these models.

The authors are careful to frame their conclusions within the limits of the evidence. Some results, particularly those for neurological deficit and motor coordination, rest on small numbers of studies with substantial statistical heterogeneity and should be interpreted with caution. Publication bias, a chronic problem in animal research in which positive results are more likely to be published than negative ones, may also inflate the apparent effect sizes. The protocol was prospectively registered on the Open Science Framework in April 2025, and the team followed PRISMA reporting guidelines, measures that improve transparency but cannot conjure data that were never collected. The related clinical picture remains sobering: an earlier systematic review by the same senior group found that excitatory amino acid inhibitors have not demonstrated clear benefit in human trials of acute traumatic brain injury, and the field’s history with NMDA antagonists, which failed despite promising animal data, haunts every new preclinical success.

Yet the timing of this analysis is propitious, because the preclinical evidence now intersects with a genuinely new clinical opportunity. Perampanel is already approved and in widespread use for epilepsy, with a growing literature documenting its safety, tolerability, brain penetration and even intravenous formulations suitable for critically ill patients. A phase-two multicentre randomised clinical trial, known as PEACE-TBI, has been designed in Japan to test whether perampanel can alleviate secondary injury after traumatic brain injury in humans. Against that backdrop, the present meta-analysis provides exactly the kind of rigorous synthesis of the animal evidence that trial designers and funders need, confirming biological plausibility for the neurobehavioural and lesion-reducing effects while honestly flagging the outcomes, motor recovery and mortality, where the signal is weak or absent. Whether AMPA receptor antagonists can finally break the decades-long cycle of failed neuroprotection in traumatic brain injury will be decided in patients, but the laboratory evidence assembled here suggests the hypothesis deserves its day in the clinic.

Subject of Research: Efficacy of AMPA receptor antagonists in preclinical animal models of traumatic brain injury

Article Title: AMPA Receptor Antagonists in Preclinical Models of Traumatic Brain Injury: A Systematic Review and Meta-analysis of Animal Studies

Article References: Gourier, S., Morin, C., Gargadennec, T., Turgeon, A. F., Poulain, C., Roquilly, A., Caillard, A., Langeron, O., & Bouras, M. (2026). AMPA Receptor Antagonists in Preclinical Models of Traumatic Brain Injury: A Systematic Review and Meta-analysis of Animal Studies. Neurocritical Care. https://doi.org/10.1007/s12028-026-02640-x

Image Credits: AI Generated

DOI: 10.1007/s12028-026-02640-x

Keywords: traumatic brain injury, AMPA receptor antagonists, excitotoxicity, neuroprotection, perampanel, systematic review, meta-analysis, preclinical models, neurobehavioural outcomes, brain lesion severity, neuroinflammation, glutamate receptors